

Marcus Laird Forrest

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2532743/publications.pdf>

Version: 2024-02-01

101
papers

6,791
citations

125106

35
h-index

68831

81
g-index

106
all docs

106
docs citations

106
times ranked

12915
citing authors

#	ARTICLE	IF	CITATIONS
1	pH-Dependent Phase Behavior and Stability of Cationic Lipid-mRNA Nanoparticles. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 690-698.	1.6	12
2	Hyaluronic acid carrier-based photodynamic therapy for head and neck squamous cell carcinoma. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 37, 102706.	1.3	3
3	Ultrasound-assisted laser thrombolysis with endovascular laser and high-intensity focused ultrasound. <i>Medical Physics</i> , 2021, 48, 579-586.	1.6	12
4	The feasibility of ultrasound-assisted endovascular laser thrombolysis in an acute rabbit thrombosis model. <i>Medical Physics</i> , 2021, 48, 4128-4138.	1.6	8
5	Cancer immunotherapy from biology to nanomedicine. <i>Journal of Controlled Release</i> , 2021, 336, 410-432.	4.8	12
6	Glatiramer acetate enhances tumor retention and innate activation of immunostimulants. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120812.	2.6	6
7	Analysis of N15-rat growth hormone after incubation with rat subcutaneous tissue and immune cells using ultra-pressure chromatography-mass spectrometry. <i>Analytical Biochemistry</i> , 2021, 634, 114425.	1.1	0
8	Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 191-205.	1.6	24
9	Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126788.	1.0	4
10	Constructing a Biomaterial to Simulate Extracellular Drug Transport in Solid Tumors. <i>Macromolecular Bioscience</i> , 2020, 20, e2000251.	2.1	6
11	Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials. <i>Journal of Controlled Release</i> , 2020, 326, 203-221.	4.8	33
12	Intratumoral Cancer Chemotherapy with a Carrier-Based Immunogenic Cell-Death Eliciting Platinum (IV) Agent. <i>Molecular Pharmaceutics</i> , 2020, 17, 4334-4345.	2.3	14
13	Effect of Iron Oxide Nanoparticles on the Oxidation and Secondary Structure of Growth Hormone. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3372-3381.	1.6	6
14	Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer. <i>Prostate</i> , 2019, 79, 628-639.	1.2	27
15	Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator. <i>Journal of Controlled Release</i> , 2019, 306, 165-176.	4.8	48
16	Implantable hyaluronic acid-deferoxamine conjugate prevents nonunions through stimulation of neovascularization. <i>Npj Regenerative Medicine</i> , 2019, 4, 11.	2.5	19
17	Glatiramer acetate persists at the injection site and draining lymph nodes via electrostatically-induced aggregation. <i>Journal of Controlled Release</i> , 2019, 293, 36-47.	4.8	25
18	Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition. <i>Molecular Cancer Research</i> , 2018, 16, 961-973.	1.5	32

#	ARTICLE	IF	CITATIONS
19	Injectable Chemotherapy Downstaged Oral Squamous Cell Carcinoma from Nonresectable to Resectable in a Rescue Dog: Diagnosis, Treatment, and Outcome. <i>Case Reports in Veterinary Medicine</i> , 2018, 2018, 1-6.	0.2	2
20	DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways. <i>Pharmaceutics</i> , 2018, 10, 144.	2.0	13
21	A Semi-Physiologically Based Pharmacokinetic Model Describing the Altered Metabolism of Midazolam Due to Inflammation in Mice. <i>Pharmaceutical Research</i> , 2018, 35, 162.	1.7	5
22	Mechanistically elucidating the in vitro safety and efficacy of a novel doxorubicin derivative. <i>Drug Delivery and Translational Research</i> , 2017, 7, 582-597.	3.0	11
23	Formation of platinum (II) as a six member ring for sustained polymeric delivery. <i>European Journal of Medicinal Chemistry</i> , 2017, 136, 452-456.	2.6	2
24	The Botanical Drug Substance Crofelemer as a Model System for Comparative Characterization of Complex Mixture Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 3242-3256.	1.6	14
25	Comparative Characterization of Crofelemer Samples Using Data Mining and Machine Learning Approaches With Analytical Stability Data Sets. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 3270-3279.	1.6	5
26	Profiling the Photochemical-Induced Degradation of Rat Growth Hormone with Extreme Ultra-pressure Chromatography-Mass Spectrometry Utilizing Meter-Long Microcapillary Columns Packed with Sub-2-µm Particles. <i>Chromatographia</i> , 2017, 80, 1299-1318.	0.7	5
27	Chemical Stability of the Botanical Drug Substance Crofelemer: A Model System for Comparative Characterization of Complex Mixture Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 3257-3269.	1.6	6
28	Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative. <i>Pharmaceutics</i> , 2017, 9, 35.	2.0	26
29	Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells. <i>Laryngoscope</i> , 2016, 126, E184-90.	1.1	12
30	Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors. <i>American Journal of Veterinary Research</i> , 2016, 77, 1005-1016.	0.3	16
31	Development and Validation of an Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Method for Quantitative Analysis of Platinum in Plasma, Urine, and Tissues. <i>Applied Spectroscopy</i> , 2016, 70, 1529-1536.	1.2	17
32	Ensuring that injectable bicarbonate-buffered lidocaine-epinephrine complies with 2015 United States Pharmacopeia (USP) compounding provisions. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 454-455.	0.6	4
33	Intratracheal Administration of Hyaluronan-Cisplatin Conjugate Nanoparticles Significantly Attenuates Lung Cancer Growth in Mice. <i>Pharmaceutical Research</i> , 2016, 33, 2517-2529.	1.7	32
34	Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1891-1900.	1.6	7
35	Routes of Administration and Dose Optimization of Soluble Antigen Arrays in Mice with Experimental Autoimmune Encephalomyelitis. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 714-721.	1.6	17
36	Nonviral Reprogramming of Human Wharton's Jelly Cells Reveals Differences Between <i>ATOH1</i> Homologues. <i>Tissue Engineering - Part A</i> , 2015, 21, 1795-1809.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice. <i>Prostate</i> , 2015, 75, 593-602.	1.2	22
38	Phospholipid Composition Modulates Carbon Nanodiamond-Induced Alterations in Phospholipid Domain Formation. <i>Langmuir</i> , 2015, 31, 5093-5104.	1.6	16
39	Targeted nanodiamonds as phenotype-specific photoacoustic contrast agents for breast cancer. <i>Nanomedicine</i> , 2015, 10, 573-587.	1.7	34
40	Combining hard and soft magnetism into a single core-shell nanoparticle to achieve both hyperthermia and image contrast. <i>Therapeutic Delivery</i> , 2015, 6, 1195-1210.	1.2	5
41	A Lanthanum-Tagged Chemotherapeutic Agent HA-Pt to Track the In Vivo Distribution of Hyaluronic Acid Complexes. <i>BAOJ Pharmaceutical Sciences</i> , 2015, 1, 1-9.	0.1	1
42	Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14008.	1.8	35
43	Improving Viability and Transfection Efficiency with Human Umbilical Cord Wharton's Jelly Cells Through Use of a ROCK Inhibitor. <i>Cellular Reprogramming</i> , 2014, 16, 91-97.	0.5	10
44	CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1221-1230.	1.7	32
45	Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates. <i>Journal of Drug Targeting</i> , 2014, 22, 648-657.	2.1	42
46	In vivo efficacy of nano hyaluronan-conjugated cisplatin for treatment of murine melanoma. <i>Journal of Drugs in Dermatology</i> , 2014, 13, 283-7.	0.4	12
47	Single-step grafting of aminoxy-peptides to hyaluronan: A simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis. <i>Journal of Controlled Release</i> , 2013, 168, 334-340.	4.8	30
48	Physical Non-Viral Gene Delivery Methods for Tissue Engineering. <i>Annals of Biomedical Engineering</i> , 2013, 41, 446-468.	1.3	140
49	Photoacoustic contrast imaging of biological tissues with nanodiamonds fabricated for high near-infrared absorbance. <i>Journal of Biomedical Optics</i> , 2013, 18, 026018.	1.4	31
50	Efficacy and Toxicity of Peritumoral Delivery of Nanoconjugated Cisplatin in an In Vivo Murine Model of Head and Neck Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2013, 139, 382.	1.2	27
51	In vivophotoacoustic imaging of breast cancer tumor with HER2-targeted nanodiamonds. , 2013, 8815, .		4
52	Adenovector-Mediated Gene Delivery to Human Umbilical Cord Mesenchymal Stromal Cells Induces Inner Ear Cell Phenotype. <i>Cellular Reprogramming</i> , 2013, 15, 43-54.	0.5	16
53	Pharmacokinetic Evaluation of a DSPE-PEG2000 Micellar Formulation of Ridaforolimus in Rat. <i>Pharmaceutics</i> , 2013, 5, 81-93.	2.0	15
54	Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas. <i>American Journal of Veterinary Research</i> , 2012, 73, 1969-1976.	0.3	26

#	ARTICLE	IF	CITATIONS
55	Photoacoustic imaging of chemotherapy-induced apoptosis in squamous cell carcinoma. Proceedings of SPIE, 2012, , .	0.8	0
56	Toxicity of nanomaterials. Chemical Society Reviews, 2012, 41, 2323-2343.	18.7	1,221
57	Lymphatic trafficking kinetics and near-infrared imaging using star polymer architectures with controlled anionic character. European Journal of Pharmaceutical Sciences, 2012, 47, 287-294.	1.9	24
58	Prodrug Strategy for PSMA-Targeted Delivery of TGX-221 to Prostate Cancer Cells. Molecular Pharmaceutics, 2012, 9, 1705-1716.	2.3	45
59	Synthesis and characterization of a multiarm poly(acrylic acid) star polymer for application in sustained delivery of cisplatin and a nitric oxide prodrug. Journal of Polymer Science Part A, 2012, 50, 2715-2724.	2.5	19
60	Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)- ϵ -poly(dl-lactide) micelle nanocarriers: Characterization and effects on pharmacokinetics in rat serum and urine. Journal of Pharmaceutical Sciences, 2012, 101, 3787-3798.	1.6	47
61	Multi-arm polymeric nanocarrier as a nitric oxide delivery platform for chemotherapy of head and neck squamous cell carcinoma. Biomaterials, 2012, 33, 3243-3253.	5.7	37
62	The Effects of PVP(Fe(III)) Catalyst on Polymer Molecular Weight and Gene Delivery Via Biodegradable Cross-Linked Polyethylenimine. Pharmaceutical Research, 2012, 29, 500-510.	1.7	4
63	Lysosomotropic Properties of Weakly Basic Anticancer Agents Promote Cancer Cell Selectivity In Vitro. PLoS ONE, 2012, 7, e49366.	1.1	32
64	Flip-flop pharmacokinetics – delivering a reversal of disposition: challenges and opportunities during drug development. Therapeutic Delivery, 2011, 2, 643-672.	1.2	194
65	Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. American Journal of Surgery, 2011, 202, 646-653.	0.9	37
66	In vivo photoacoustic imaging of chemotherapy-induced apoptosis in squamous cell carcinoma using a near-infrared caspase-9 probe. Journal of Biomedical Optics, 2011, 16, 116026.	1.4	24
67	Lymphatic drug delivery: therapy, imaging and nanotechnology. Advanced Drug Delivery Reviews, 2011, 63, 865-866.	6.6	5
68	Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Advanced Drug Delivery Reviews, 2011, 63, 901-908.	6.6	212
69	Advances in lymphatic imaging and drug delivery. Advanced Drug Delivery Reviews, 2011, 63, 876-885.	6.6	67
70	A sensitive near-infrared fluorescent probe for caspase-mediated apoptosis: Synthesis and application in cell imaging. Drug Discoveries and Therapeutics, 2011, 5, 220-226.	0.6	8
71	Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies. Therapeutic Delivery, 2011, 2, 1467-1484.	1.2	8
72	Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. Journal of Controlled Release, 2010, 146, 212-218.	4.8	145

#	ARTICLE	IF	CITATIONS
73	Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. Journal of Pharmaceutical Sciences, 2010, 99, 2018-2031.	1.6	139
74	Pharmacokinetics and Disposition of a Localized Lymphatic Polymeric Hyaluronan Conjugate of Cisplatin in Rodents. Journal of Pharmaceutical Sciences, 2010, 99, 2664-2671.	1.6	50
75	Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. International Journal of Pharmaceutics, 2010, 392, 156-163.	2.6	81
76	The Role of Lysosomes in Limiting Drug Toxicity in Mice. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 120-128.	1.3	30
77	Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck. Therapeutic Delivery, 2010, 1, 237-245.	1.2	26
78	Intracellular Distribution-based Anticancer Drug Targeting: Exploiting a Lysosomal Acidification Defect Associated with Cancer Cells. Molecular and Cellular Pharmacology, 2010, 2, 131-136.	1.7	14
79	Alkyne- and 1,6-elimination- succinimidyl carbonate - terminated heterobifunctional poly(ethylene) Tj ETQq1 1 0.784314 rgBT /Overlock 0,6	0.6	2
80	A Cremophor-Free Formulation for Tanespimycin (17-AAG) Using PEO-b-PDLLA Micelles: Characterization and Pharmacokinetics in Rats. Journal of Pharmaceutical Sciences, 2009, 98, 1577-1586.	1.6	42
81	Effects of nanomaterial physicochemical properties on in vivo toxicity. Advanced Drug Delivery Reviews, 2009, 61, 457-466.	6.6	707
82	Nanoparticles for biomedical imaging. Expert Opinion on Drug Delivery, 2009, 6, 1175-1194.	2.4	369
83	A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo. American Journal of Surgery, 2009, 198, 781-786.	0.9	46
84	Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opinion on Drug Delivery, 2009, 6, 785-792.	2.4	142
85	Paclitaxel Prodrugs with Sustained Release and High Solubility in Poly(ethylene) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 267 Td Cytotoxicity. Pharmaceutical Research, 2008, 25, 194-206.	1.7	109
86	Clinical toxicities of nanocarrier systems. Advanced Drug Delivery Reviews, 2008, 60, 929-938.	6.6	277
87	Clinical developments in drug delivery nanotechnology. Advanced Drug Delivery Reviews, 2008, 60, 861-862.	6.6	39
88	Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. Journal of Controlled Release, 2008, 129, 33-40.	4.8	47
89	Intralymphatic Chemotherapy Using a Hyaluronan-Cisplatin Conjugate. Journal of Surgical Research, 2008, 147, 247-252.	0.8	116
90	Micellization and Drug Solubility Enhancement Part II. , 2008, , 307-371.		2

#	ARTICLE	IF	CITATIONS
91	Biotin-Triggered Release of Poly(ethylene glycol)-Avidin from Biotinylated Polyethylenimine Enhances In Vitro Gene Expression. <i>Bioconjugate Chemistry</i> , 2007, 18, 746-753.	1.8	28
92	pH-Responsive Multi-PEGylated Dual Cationic Nanoparticles Enable Charge Modulations for Safe Gene Delivery. <i>ChemMedChem</i> , 2007, 2, 1321-1327.	1.6	41
93	Poly(aspartate-g-PEI800), a polyethylenimine analogue of low toxicity and high transfection efficiency for gene delivery. <i>Biomaterials</i> , 2007, 28, 4889-4900.	5.7	105
94	Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(μ -caprolactone) micelles of rapamycin. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 133-144.	1.1	54
95	In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(μ -caprolactone) micelles. <i>Journal of Controlled Release</i> , 2006, 110, 370-377.	4.8	171
96	Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	4.8	58
97	Amphiphilic block copolymer micelles for nanoscale drug delivery. <i>Drug Development Research</i> , 2006, 67, 15-22.	1.4	137
98	Cyclodextrin-polyethylenimine conjugates for targeted in vitro gene delivery. <i>Biotechnology and Bioengineering</i> , 2005, 89, 416-423.	1.7	120
99	Partial Acetylation of Polyethylenimine Enhances In Vitro Gene Delivery. <i>Pharmaceutical Research</i> , 2004, 21, 365-371.	1.7	222
100	A Degradable Polyethylenimine Derivative with Low Toxicity for Highly Efficient Gene Delivery. <i>Bioconjugate Chemistry</i> , 2003, 14, 934-940.	1.8	367
101	On the Kinetics of Polyplex Endocytic Trafficking: Implications for Gene Delivery Vector Design. <i>Molecular Therapy</i> , 2002, 6, 57-66.	3.7	124